Robo.ai Inc. enters the second half of May with one of the most dramatic short-squeeze setups in the small-cap universe — a stock up 113% on the week, shorts tripling their exposure, and borrow costs screaming above 500%.
The borrow market tells the most striking story this week. Cost to borrow has exploded to 509% annualised — up from just 29% a week ago, a 1,524% rise in five sessions. That means it now costs roughly $5 to borrow $1 worth of stock for a year, making new short positions extraordinarily expensive to initiate or hold. Availability has tightened to just 26% of short interest, meaning there are roughly one-quarter of a share available for every share already lent out. That is deep into "very tight" territory. The borrow market has essentially seized up around a rapidly moving underlying.
Short positioning itself has accelerated into this tightness, which is the central tension. Estimated short interest climbed to 8.2% of free float by May 12 — up from just 2.0% a week earlier and from near-zero following a short reset in late April. The absolute share count tripled in a week to roughly 962,000 shares. That kind of build-rate in a ~$21 million market-cap name, against a stock already up 64% over the past month, is an aggressive wager. The ORTEX short score has surged to 74.2 — up from 58 at the start of May — placing AIIO among the most heavily pressured small-cap names on the platform right now. DTC rank scores in the 52nd percentile, relatively neutral, but the combination of rising SI, evaporating availability and exploding borrow costs points to a lending market under acute stress.
The catalyst behind the move is a corporate one. On May 8, Robo.ai announced an agreement to acquire 100% of the equity in Neurovia AI Limited for $100 million — a deal that sent the stock sharply higher and appears to have triggered a fresh wave of short interest as traders debated whether a ~$21 million market-cap company could credibly fund a nine-figure acquisition. That scepticism is now extremely expensive to maintain. The gap between the stock's market cap and the stated deal consideration remains a live debate in the tape. No analyst coverage is available to contextualise the deal's terms or valuation.
Earnings history adds another variable. The last four reporting events produced one-day moves of +4.5%, +27.8%, -20.6%, and -6.8% respectively — a wide and unpredictable range. The next event is scheduled for May 27. With the stock up more than 100% on the week heading into that date, the setup going into results carries significant two-way risk. The April 30 print produced only a modest 4.5% next-day move despite the volatile backdrop, but the 5-day drift turned flat, suggesting any announcement-day pop can fade quickly.
Institutional ownership is thin and concentrated. The top disclosed holders — Vision Path Holdings, Alan Wu, and Iconic Investment One — collectively control over 31% of shares, all last reported in September 2025 with zero change. Conventional institutional float is minimal, making the borrow pool small by design and explaining why availability has tightened so dramatically even at relatively modest short share counts. The options data in the snapshot predates 2023 and carries no current relevance.
What to watch: whether borrow costs hold above 500% or begin to ease as shorts cover into the May 27 earnings date — and whether the Neurovia deal receives any further detail on financing that shifts the market's view on the acquisition's credibility.
See the live data behind this article on ORTEX.
Open AIIO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
